1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma

M.W. Lucas; Elisa A. Rozeman; Judith M. Versluis; Alexander M. Menzies; Hanna Eriksson; B. van de Wiel; Richard A Scolyer; H.V. van Thienen; Henk Mallo; Maria Gonzalez; L. Landman; A. Torres Acosta; Lindsay G. Grijpink-Ongering; John B.A.G. Haanen; Alexander C.J. van Akkooi; Georgina V. Long; Christian U. Blank

doi:10.1016/j.annonc.2023.09.2230

Related publications

Article2021

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

Judith M. Versluis, Irene L. M. Reijers, Elisa A. Rozeman, Alexander M. Menzies, Alexander C.J. van Akkooi, Michel W.J.M. Wouters, Sydney Ch’ng, Robyn P.M. Saw, Richard A Scolyer, Bart A. van de Wiel, Bastian Schilling, Georgina V. Long, Christian U. Blank

Article2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, Bart A van de Wiel, Alexander M Menzies, Marta Lopez-Yurda, Lotte L Hoeijmakers, Robyn P M Saw, Judith M Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, Alejandro Torres Acosta, Winan J. van Houdt, Serigne N Lo, Anke M J Kuijpers, Andrew Spillane, W Martin C Klop, Thomas E Pennington, Charlotte L Zuur, Kerwin F Shannon, Beatrijs A Seinstra, Robert V Rawson, John B A G Haanen, Sydney Ch'ng, Kishan A T Naipal, Jonathan Stretch, Johannes V van Thienen, Michael A Rtshiladze, Sofie Wilgenhof, Rony Kapoor, Aafke Meerveld-Eggink,

Article2024

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long

Article2025

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study

Georgina V. Long, Victoria Atkinson, Serigne Lo, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Maria Gonzalez, Grant A. McArthur, Alexander M Menzies

Article2024

LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial

M.W. Lucas, A.M. Menzies, Marta López‐Yurda, Richard A. Scolyer, B. van de Wiel, R.P.M. Saw, W. Van Houdt, Nigel Maher, A. Torres Acosta, M. Boers-Sonderen, G. Hospers, M.S. Carlino, Jan Willem de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank

1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma

Discussion(0)

Related publications

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study

LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial